Back to discover
Disease
Lung large cell carcinoma
Active therapeutic pipeline
Also known as anaplastic lung carcinoma, large cell carcinoma of lung, large cell carcinoma of the lung, large cell lung cancer+3 more
anaplastic lung carcinoma, large cell carcinoma of lung, large cell carcinoma of the lung, large cell lung cancer, large cell lung carcinoma, large cell undifferentiated lung carcinoma, LCLC.
5
Clinical trials
1
Associated genes
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
Executive briefingUpdating summary…Momentum: Low
Key developments
- 2 clinical trials expected to report results, the earliest in Q2 2027.
Upcoming Milestones
- Q2 2027A Phase 2 Randomized Study of the BER Inhibitor TRC102 in Combination With Standard Pemetrexed-Platinum-Radiation in Stage III Non-Squamous Non-Small Cell Lung Cancer
- Q2 2028Phase II Randomized Clinical Trials Comparing Immunotherapy Plus Stereotactic Ablative Radiotherapy (I-SABR) Versus SABR Alone for Stage I, Selected Stage IIa, or Isolated Lung Parenchymal Recurrent Non-Small Cell Lung Cancer: I-SABR
Major developments
Major trial resultsHigh impact
Results posted2026-08-04
Clinical MilestonesViewHide
Results posted
- 2026-08-04A Dose Finding Study Followed by Phase II Randomized, Placebo-Controlled Study of Veliparib (ABT-888) Added to Chemoradiotherapy With Carboplatin and Paclitaxel for Unresectable Stage III Non-small Cell Lung Cancer (NSCLC), (NCI Study Number 8811)Results posted
- 2026-07-07A Pilot Trial of Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Docetaxel and the Addition of Bevacizumab (NSC-704865) in Three Cohorts of Patients With Inoperable Locally Advanced Stage III Non-small Cell Lung CancerResults posted
Results expected
- 2026-08-13A Phase 2 Randomized Study of the BER Inhibitor TRC102 in Combination With Standard Pemetrexed-Platinum-Radiation in Stage III Non-Squamous Non-Small Cell Lung CancerResults expected Q2 2027
- 2026-06-22Phase II Randomized Clinical Trials Comparing Immunotherapy Plus Stereotactic Ablative Radiotherapy (I-SABR) Versus SABR Alone for Stage I, Selected Stage IIa, or Isolated Lung Parenchymal Recurrent Non-Small Cell Lung Cancer: I-SABRResults expected Q2 2028
Activity timeline4
- 2026-08-13ClinicalA Phase 2 Randomized Study of the BER Inhibitor TRC102 in Combination With Standard Pemetrexed-Platinum-Radiation in Stage III Non-Squamous Non-Small Cell Lung CancerResults expected Q2 2027
- 2026-08-04ClinicalA Dose Finding Study Followed by Phase II Randomized, Placebo-Controlled Study of Veliparib (ABT-888) Added to Chemoradiotherapy With Carboplatin and Paclitaxel for Unresectable Stage III Non-small Cell Lung Cancer (NSCLC), (NCI Study Number 8811)Results posted
- 2026-07-07ClinicalA Pilot Trial of Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Docetaxel and the Addition of Bevacizumab (NSC-704865) in Three Cohorts of Patients With Inoperable Locally Advanced Stage III Non-small Cell Lung CancerResults posted
- 2026-06-22ClinicalPhase II Randomized Clinical Trials Comparing Immunotherapy Plus Stereotactic Ablative Radiotherapy (I-SABR) Versus SABR Alone for Stage I, Selected Stage IIa, or Isolated Lung Parenchymal Recurrent Non-Small Cell Lung Cancer: I-SABRResults expected Q2 2028
Clinical trials
The current development programme across all trial phases.
Clinical programme
5
4
0
1
Associated genes
Genes associated with this disease in the canonical knowledge graph (Open Targets evidence). Number shows the association score.
Reference
Authoritative identity, definition & identifiers.
Synonyms
anaplastic lung carcinoma, large cell carcinoma of lung, large cell carcinoma of the lung, large cell lung cancer, large cell lung carcinoma, large cell undifferentiated lung carcinoma, LCLC
References & data sources
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Related entities are derived from literature co-mention (studied together) — associative, not causal.